Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Ligand Pharmaceuticals Incorporated currently loses $36.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Ligand Pharmaceuticals beat expectations on both the top and bottom line in the third fiscal quarter of 2026, based on preliminary results reported October 29, 2026, with adjusted EPS of $2.67 topping the $2.33 estimate (+14.6%) even as revenue fell 31.8% year over year to roughly $78.7 million (down from about $115.5 million a year ago) and still came in above consensus at $78.7 million versus $77.0 million (+2.3%). On the bottom line, adjusted EPS declined 13.6% from $3.09 a year ago, and net income was not provided with the preliminary figures. The company’s model centers on licensing and supporting a portfolio of marketed medicines and its Captisol formulation technology across areas including oncology, vaccines, central nervous system, and anti-infective products. For the next period, consensus calls for EPS of $3.07 on revenue of $96.9 million.
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biotechnology company that licenses and supports a portfolio of marketed medicines and formulation technology for pharmaceutical companies worldwide. Its business spans oncology, vaccines, central nervous system, anti-infective, cardiovascular, and bone-health products, and generated $268.1 million of revenue in FY2025.
Today's Snapshot
LGND closed 1.7% above yesterday's close, outperforming a weaker sector. Trading was busier than usual, with volume roughly twice its usual level.
Trading Volume
Above 10d avg 198.0K
378.7K
vs S&P 500 Today
Outperforming Market
+1.93%
Updated: November 18, 2026 at 21:17 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$261.04 - $306.96Sell
- RSI (14)44.92Neutral
- Stochastic %K (14, 3, 3)13.83Buy
- MACD Level (12, 26)-0.22Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.